PaxMedica sees stock surge following positive Phase 2 ASD trial results

PaxMedica (NASDAQ:PXMD) witnessed a nearly 67% surge in its stock following the significant results from its Phase 2 clinical trials. The trials, which were published in the Annals of General Psychiatry, revealed substantial improvements in Autism Spectrum Disorder (ASD) patients treated with a 10 mg/kg dosage of suramin over a period of 16 weeks. This news led to an intense trading session with approximately 23 million PXMD shares changing hands.

The NASDAQ-listed biopharmaceutical firm is known for specializing in anti-purinergic drug therapies (APT). The recent research was a 14-week randomized, double-blind, placebo-controlled study that involved 52 boys aged between 4 and 15 years. The study was led by PaxMedica’s Chief Medical Officer, Dr. David Hough.

The research focused on the efficacy and safety of a 10 mg/kg suramin dosage. It showed significant improvements in core symptoms among the suramin group compared to the placebo group. These advancements were measured using the Clinical Global Impressions-Improvement (CGI-I) scale.

Dr. David Hough emphasized the potential of suramin as an effective treatment for ASD. He stated that the significant improvements observed in the trial participants point towards a promising future for this treatment option.

While PaxMedica was at the center of this trading frenzy, other notable stock movements included Vivid Seats (SEAT), which saw a $240 million value increase, and an 11% rise in Ault Alliance (AULT) following a financing agreement. Lucid Motors (NASDAQ:) also made headlines by adopting Tesla (NASDAQ:)’s charging standard.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.